Progression free survival rate
This bispecific antibody stops immunosuppression and blood supply process both responsible for progression of the cancer. The drug is now approved in combo therapy for cancer in China!
Different MOA but one could not ignore long term efficacy of cancer drugs and their place in the market as a stand alone drug or in combination with chemotherapy.
I thought it was interesting to bring this up as sudocetaxel zendusortide managed to stabilize the disease for long time.
https://ca.finance.yahoo.com/news/summit-shares-soar-lung-cancer-195343904.html
https://ca.finance.yahoo.com/news/ivonescimab-combination-chemotherapy-approved-china-230000301.html